Patents by Inventor Thomas W. Lyons

Thomas W. Lyons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240239788
    Abstract: Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: April 15, 2022
    Publication date: July 18, 2024
    Inventors: David L. Sloman, Gianni Chessari, Patrick Schöpf, Steven Howard, Yuichi Kawai, Kazuaki Shibata, Hiroki Asakura, Takao Uno, Takeshi Sagara, Masayuki Nakamura, Yu Kobayakawa, David Jonathan Bennett, Indu Bharathan, Thomas H. Graham, Yongxin Han, Zahid Hussain, Xiaoshen Ma, Mihir Mandal, Ryan D. Otte, Anandan Palani, Uma Swaminathan, Mycah Uehling, Yingchun Ye, Ryan Chau, Alec H. Christian, Symon Gathiaka, Timothy J. Henderson, Elisabeth T. Hennessy, Andrew J. Hoover, Shuhei Kawamura, Igri Kolaj, Thomas W. Lyons, Matthew J. Mitcheltree, Aaron Sather
  • Patent number: 10618892
    Abstract: This invention provides an improved processes for the preparation of verubecestat (Compound of Formula (I)), a potent inhibitor of BACE-1 and BACE-2.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: William J. Morris, David Thaisrivongs, Thomas W. Lyons
  • Publication number: 20200039975
    Abstract: This invention provides an improved processes for the preparation of verubecestat (Compound of Formula (I)), a potent inhibitor of BACE-1 and BACE-2.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 6, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: William J. Morris, David Thaisrivongs, Thomas W. Lyons